Add BrightSurf on Google Email

New study identifies genetic markers that could guide emerging prostate cancer treatments

Researchers at the University of Texas MD Anderson Cancer Center have identified genetic factors that determine whether prostate cancers are susceptible to ferroptosis. SPOP mutations and CHD1 deletions could serve as biomarkers to help identify patients who may benefit from emerging ferroptosis-based therapies.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·TypeExperimental study·DateJul 2, 2026

Should lowest-risk prostate ‘cancer’ still be called cancer? Study suggests changing the name could save lives

Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.

UCLA researchers awarded $1.7 million Department of Defense grant to advance next-generation CAR T-cell therapies for prostate cancer

Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.

Study finds prostate cancer screening discussions are rare – but make a big difference

A new study found that conversations about prostate cancer screening are uncommon in primary care visits but lead to higher screening rates when they do occur. The study suggests a gap between national guidelines and clinical practice, highlighting the importance of shared decision-making for individualized care.

SourceMedical University of South Carolina·JournalSouthern Medical Journal·TypeObservational study·DateJun 22, 2026

Cancer's hidden escape route

Prostate cancer cells use the PIM1 protein to survive treatment by activating autophagy, a cellular recycling process. Researchers have discovered a potential strategy to overcome this resistance by removing the PIM1 protein entirely using a proteolysis-targeting chimera.

SourceMedical University of South Carolina·JournalCancer Letters·TypeExperimental study·DateJun 16, 2026

Largest study of prostate cancer in Brazil’s public health system reveals racial inequalities in diagnosis and treatment

A recent study analyzing 670,000 patients found a higher frequency of advanced disease among non-white men and differences in access to modern therapies. The study also revealed significant racial inequalities in treatment costs, with white patients receiving 16.2% more funding.

SourceD'Or Institute for Research and Education·JournalJournal of Clinical Oncology·DateMay 31, 2026

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis and death

A phase 3 clinical trial found that apalutamide plus hormone therapy before and after surgery reduced the risk of metastasis or death by 20% compared to hormone therapy alone. Patients treated with this regimen had a higher pathologic response rate and experienced delayed subsequent therapy.

SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·DateMay 31, 2026

Researchers identify new target to prevent aggressive form of prostate cancer

Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateMay 28, 2026

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy

Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·DateMay 20, 2026

Just two radiotherapy sessions given over eight days can treat prostate cancer without any extra side effects

A study published by the European Society for Radiotherapy and Oncology found that delivering radiotherapy in just two sessions over eight days is safe and effective for treating prostate cancer. The treatment had no additional side effects compared to the standard five doses, making it a convenient option for patients.

Screening modestly reduces prostate cancer deaths

Screening with a PSA blood test reduces prostate cancer deaths by approximately 2 for every 1,000 men screened. The review found that 500 men would need to be invited to screening to prevent one prostate cancer death.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateMay 14, 2026

Testosterone treatment improved sexual and physical function for men after prostate cancer surgery

A randomized clinical trial found that testosterone treatment significantly improved sexual activity, sexual desire, and quality of life scores in men after prostate cancer surgery. The treatment also improved body composition and aerobic performance without increasing the risk of biochemical recurrence.

SourceMass General Brigham·JournalJAMA Internal Medicine·TypeRandomized controlled/clinical trial·DateMay 11, 2026

Drugging the undruggable: Scientists achieve million-fold leap in targeting elusive cancer proteins

Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.

SourceUniversity of British Columbia·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateApr 27, 2026

Federal housing assistance may lead to improved two-year survival among older people with prostate cancer

New research suggests that federal housing assistance may lead to better two-year survival chances among older men with prostate cancer. The study found a 12% lower risk of death in men who received housing assistance compared to those without it.

SourceUniversity of California - Los Angeles Health Sciences·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateApr 21, 2026

First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy

Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateApr 2, 2026

Scalable platform sheds light on how cancer spreads

A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.

SourceRice University·JournalAdvanced Healthcare Materials·TypeExperimental study·DateMar 26, 2026

Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance

A study by the University of Texas M. D. Anderson Cancer Center found that men with low testosterone levels are 60% more likely to have their prostate cancer progress to a more aggressive state during surveillance. Low testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Journal of Urology·DateMar 10, 2026